N Engl J Med July 2005 PMID 16034009

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Christoph Wanner, Vera Krane, Winfried März, Manfred Olschewski, Johannes F E Mann, Günther Ruf, Eberhard Ritz

Full text PDF Download social card

Mentions

Peak: 5 in Nov 2021

across 4 sources since Feb 2019

Extended reach

162,111

potential audience

Total likes

497

Video views

19,880

Mentions per month

Feb 2019 – Nov 2025

Where it's discussed

X / Twitter16 posts
Blogs6 articles
YouTube4 videos
News4 articles

AI synopsis

What people are saying

The discussions reveal skepticism about the clinical significance of atorvastatin in this context, referencing past studies like the 2005 NEJM publication, with phrases like 'no benefit' and 'disappointment,' which reflect a critical tone. The tone and references to multiple trials underscore a cautious, analytical approach that recognizes the ongoing controversy and the nuanced impact of this research.

AgreementLow agreement

Most discussions reflect skepticism or disappointment toward the findings, with some citing prior studies showing no benefit.

InterestModerate interest

Posts show moderate interest, especially when highlighting ongoing debates or previous related studies.

EngagementModerate engagement

Users actively discuss multiple trials and limitations, indicating ongoing engagement.

ImpactNeutral impact

Discussions suggest limited perceived impact on clinical practice, though some emphasize the importance of the findings.

Abstract in brief

The study found that in patients with type 2 diabetes on hemodialysis, atorvastatin significantly lowered LDL cholesterol levels and reduced the risk of overall cardiac events and cardiovascular death, but did not significantly impact stroke or total mortality in a four-year follow-up.
While atorvastatin decreased the occurrence of major cardiac issues, it showed limited effect on cerebrovascular events and no significant influence on overall death rates from all causes.
The results suggest that atorvastatin can be beneficial in reducing certain cardiovascular risks for diabetic patients undergoing dialysis, but its impact on stroke and overall mortality remains limited.

Read the full abstract

All mentions

Understanding Kidney Chemistry and Managing Chronic Kidney Disease Effectively

Your kidneys balance calcium, phosphorus, and vitamin D with precision. When disrupted by chronic kidney disease, it weakens bones and causes artery calcification. Effective management includes phosphorus binders and…

Sean Hashmi, MD · Sep 2, 2025 16,445 views

Inflammation and Cardiovascular Risk Reduction in Chronic Kidney Disease

Prof Dr Dr Thimoteus Speer discusses the role of inflammatory signaling pathways in the high cardiovascular risk among CKD patients and explores how IL6 inhibition with Ziltivekimab, currently under investigation in the…

MARKUS at HOMe · Jul 14, 2023 2,616 views

Target Blood Pressure Values for High-Risk Patients Explained

Prof. Johannes Mann discusses target blood pressure values for individuals with elevated cardiovascular risk based on the STEP trial presented at the European Society of Cardiology. The conversation interprets results…

MARKUS at HOMe · Nov 12, 2021 819 views

Epidemiological Trends in Cardiovascular Events and Bleeding in Advanced CKD

Dr AnneLaure Faucon and Dr Marie Evans analyze epidemiological data on cardiovascular events and bleeding complications in advanced CKD patients from the Swedish Renal Registry, highlighting key findings and clinical…

MARKUS at HOMe · Nov 24, 2025 0 views

TheVitaDoc

@MCotterMD · X

@judgesmailsKC @Marion436842126 I found this PDF of the study https://t.co/eUwFUMPNhd

Mar 7, 2025 · 1 like · 18,389 followers View post →

やっさん

@kuanyi_vet · X

RT @keisuke4713: statinは糖尿病に禁忌糖尿病の冠動脈疾患が予防されず ASPEN https://t.co/Tfbem7rwsP 4D https://t.co/5sbH7VUevr 糖尿に禁忌 https://t.co/Q1POpNJUvx cho…

Feb 22, 2025 · 1 share · 725 followers View post →

tune

@keisuke4713 · X

Feb 22, 2025 · 4 likes · 1 share · 3,744 followers View post →

Austin Dudzinski, PharmD, BCACP

@DudzLightLime · X

Nov 10, 2024 · 3 likes · 890 followers View post →

Austin Dudzinski, PharmD, BCACP

@DudzLightLime · X

@pcny_nyc Cont (sorry ran out of text): https://t.co/XhiG6YiLui (ASPEN) https://t.co/Ct6Lhp2pGO (AURORA) https://t.co/N7WBVCdszD (CORONA) https://t.co/I9dYK0qy1J (GISSI-HF) https://t.co/aAiyngdbBL (GISSI-P) https://t.co/MscJN7V4Di (St Francis Heart) https://t.co/JHigjQTQXm (4D)

Oct 4, 2024 · 1 like · 890 followers View post →

MacroFour

@MacroFour · X

@FrogHarmless That trial is not in T2 diabetes. Here is another one that is. https://t.co/SZiNmGQC36

Aug 31, 2024 · 6,056 followers View post →

CKJ

@CKJsocial · X

Nephrologists in their 50s&older will surely remember the NEJM publication in 2005 from the same study which showed no effect of atorvastatin on a number of primary endpoints in this group of patients https://t.co/uQmwJe0L6Z & the ensuing disappointment within the renal community

Oct 3, 2023 · 15,144 followers View post →

MacroFour

@MacroFour · X

@Drlipid @DrPaulMason Fact Check: False https://t.co/SZiNmH7F56 https://t.co/uJqfQvOgCS

Aug 11, 2022 · 7 likes · 6,056 followers View post →

MacroFour

@MacroFour · X

@CornivoreA It was not listed as a study limitation. Are you saying that the researchers were incompetent despite funding from Pfizer from $billion drug sales? Is there the same problem here? https://t.co/SZiNmH7F56

Jul 15, 2022 · 1 like · 6,056 followers View post →

MacroFour

@MacroFour · X

@MichaelAlbertMD @nicknorwitz @MichaelMindrum Here is another in a subgroup of those on dialysis with T2D. Again, no benefit for these patients either. https://t.co/SZiNmH7F56

Nov 21, 2021 · 1 like · 6,056 followers View post →

Manuel Gaxiola

@cardiogax · X

2005. ¿Algunas palabras @kidney_doctor @rafavaldeznefro @OlynkaV ? Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis | NEJM https://t.co/naLUBx02MA

Nov 13, 2021 · 4 likes · 7,986 followers View post →

MacroFour

@MacroFour · X

@ethanjweiss @DaveKeto @davidludwigmd @Plant_proof If it were just one study ... but then we have this RCT in a high-risk group of people with diabetes. LDL lowered 42% & also no benefit! https://t.co/SZiNmH7F56

Nov 9, 2021 · 6,056 followers View post →

MacroFour

@MacroFour · X

@wrigley_dr @DaveKeto @Plant_proof @davidludwigmd @The_Nutrivore LDL reduced 42% but ... "... no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis." https://t.co/SZiNmH7F56

Nov 9, 2021 · 6,056 followers View post →

Faruk £RT£N

@faruk_ertn · X

Kaynaklar 1)https://t.co/bjPyiYtsYe 2)https://t.co/OKFEwiyoUX 3)https://t.co/jw8O6p6e04 4) https://t.co/YLj7FR1PbO 5)https://t.co/OPxrY0oLA6 6)https://t.co/hawQYTlKhh 8)https://t.co/srpTyAn14z 9)https://t.co/OGNZzjghKA 10)https://t.co/e71qZKl95a 11) https://t.co/gJPJrtqKkT

Oct 3, 2020 · 285 followers View post →

Edgar V. Lerma

@edgarvlermamd · X

@aishaikh 4D Study: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis from @NEJM #Nephpearls

Apr 19, 2019 · 5 likes · 2 shares · 33,860 followers View post →

Larronde Esteban

@EstebanDL · X

13. 2 estudios eran pacientes en dialisis AURORA https://t.co/BXE0yLCJuI Rosuvastina vs placebo GDDSI https://t.co/dgZdgmPTzD Atorvastina vs placebo NINGUNO DE LOS DOS MEJORÓ MORTALIDAD NI EVENTOS

Feb 6, 2019 · 23,975 followers View post →

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Understanding Kidney Chemistry and Managing Chronic Kidney Disease Effectively

Inflammation and Cardiovascular Risk Reduction in Chronic Kidney Disease

Target Blood Pressure Values for High-Risk Patients Explained

Epidemiological Trends in Cardiovascular Events and Bleeding in Advanced CKD